Elisabeth Operschall

Author

Also Known As

E J OPERSCHALL, E Operschall, E. Operschall, Elisabeth Operschall

Publications

607

Citations

H-Index

Concepts

All Affiliations

Elisabeth Operschall is an author at Bayer (Germany) specializing in economic evaluation, health care finance, and pulmonary medicine.

#	Concept	H-Index	Publications	Citations
1	Medicine	1	1	75
2	Public Health	1	1	75
3	Health Policy	1	1	75
4	Pulmonary Medicine	1	1	75
5	Health Care Finance	1	1	75

Elisabeth Operschall

Publications

508

Citations

H-Index

Page 1

	Year	Citations
RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis Anthony De Soyza, Timothy R. Aksamit, Tiemo-Joerg Bandel, European Respiratory Journal	2018	182
RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis Timothy R. Aksamit, Anthony De Soyza, Tiemo-Joerg Bandel, European Respiratory Journal	2018	180
Economic Burden of Non-Cystic Fibrosis Bronchiectasis in the First Year after Diagnosis from A US Health Plan Perspective Vijay N. Joish, Monica Spilsbury-Cantalupo, Elisabeth Operschall, Applied Health Economics and Health Policy First YearNon-cystic Fibrosis BronchiectasisHealth EconomicsHealth PolicyAdvanced Lung Disease	2013	75
The RESPIRE trials: Two phase III, randomized, multicentre, placebo-controlled trials of Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) in non-cystic fibrosis bronchiectasis Timothy R. Aksamit, Tiemo-Joerg Bandel, Margarita Criollo, Contemporary Clinical Trials	2017	44
Ciprofloxacin DPI: a randomised, placebo-controlled, phase IIb efficacy and safety study on cystic fibrosis Henry L. Dorkin, Doris Staab, Elisabeth Operschall, BMJ Open Respiratory Research	2015	27

Page 1